Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Sep;47(2):134-142.
doi: 10.1111/j.1600-079X.2009.00703.x. Epub 2009 Jul 13.

Therapeutic potential of melatonin in traumatic central nervous system injury

Supriti Samantaray  1 , Arabinda Das  1 , Nakul P Thakore  1 , Denise D Matzelle  1 , Russel J Reiter  2 , Swapan K Ray  3 , Naren L Banik  1
Affiliations
Review

Therapeutic potential of melatonin in traumatic central nervous system injury

Supriti Samantaray et al. J Pineal Res. 2009 Sep.

Abstract

A vast literature extolling the benefits of melatonin has accumulated during the past four decades. Melatonin was previously considered of importance to seasonal reproduction and circadian rhythmicity. Currently, it appears to be a versatile anti-oxidative and anti-nitrosative agent, a molecule with immunomodulatory actions and profound oncostatic activity, and also to play a role as a potent neuroprotectant. Nowadays, melatonin is sold as a dietary supplement with differential availability as an over-the-counter aid in different countries. There is a widespread agreement that melatonin is nontoxic and safe considering its frequent, long-term usage by humans at both physiological and pharmacological doses with no reported side effects. Endeavors toward a designated drug status for melatonin may be enormously rewarding in clinics for treatment of several forms of neurotrauma where effective pharmacological intervention has not yet been attained. This mini review consolidates the data regarding the efficacy of melatonin as an unique neuroprotective agent in traumatic central nervous system (CNS) injuries. Well-documented actions of melatonin in combating traumatic CNS damage are compiled from various clinical and experimental studies. Research on traumatic brain injury and ischemia/reperfusion are briefly outlined here as they have been recently reviewed elsewhere, whereas the studies on different animal models of the experimental spinal cord injury have been extensively covered in this mini review for the first time.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Trauma to the spinal cord is represented as a continuous processe of tissue destruction, abortive repair, and wound healing around the injury site. Possible windows of therapeutic interventions, especially for neuroprotective/neurorestorative modalities, have been highlighted wherein agents like melatonin can act (SC, spinal cord).
Fig. 2.
Fig. 2.
The therapeutic potentials of melatonin in the treatment of spinal cord injury (SCI).
See this image and copyright information in PMC

References

    1. Miller SM. Methylprednisolone in acute spinal cord injury: a tarnished standard. J Neurosurg Anesthesiol 2008; 20:140–142. - PubMed
    1. Rozet I. Methylprednisolone in acute spinal cord injury: is there any other ethical choice? J Neurosurg Anesthesiol 2008; 20:137–139. - PubMed
    1. Amar AP, ed. Surgical Management of Spinal Cord Injury: Controversies and Consensus. Blackwell, Hoboken, 2007.
    1. Lindsey RZGSP. Injury to the vertebrae and spinal cord. In: Trauma. Moore EF, Feliciano DV, Mattox KL, eds. McGraw-Hill, Medical Publication Division, New York, 2003; pp. 459–492.
    1. Lerner AB, Case JD, Takahashi Y et al. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc 1958; 80:2587.

MeSH terms

LinkOut - more resources